1.49
+0.09(+6.43%)
Currency In USD
Address
245 Main Street
Boston, MA 02142
United States of America
Phone
781-797-0979
Website
Sector
Healthcare
Industry
Biotechnology
Employees
79
First IPO Date
May 06, 2022
| Name | Title | Pay | Year Born |
| Dr. James G. McArthur Ph.D. | President, Chief Executive Officer, Treasurer, Secretary & Director | 850,668 | 1962 |
| Dr. Paul D. Streck M.B.A., M.D. | Executive Vice President and Head of Research & Development | 332,733 | 1964 |
| Mr. Noel P. Donnelly M.B.A. | Chief Financial Officer | 633,705 | 1970 |
| Ms. Mary Beth DeLena J.D. | General Counsel & Secretary | 0 | 1968 |
| Ms. Emiko Bryant | Chief of Staff, HR & Operations | 0 | N/A |
| Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs | 0 | N/A |
| Dr. Michael Gait Ph.D. | Founder & Scientific Advisory Board Member | 0 | N/A |
| Dr. Afsaneh Mohebbi Ph.D. | Senior Vice President of Portfolio and Program Management | 0 | N/A |
| Mr. Kyle Breidenstine CPA, M.B.A. | Vice President of Finance & Controller | 0 | N/A |
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.